Contact Supplier

Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Locnartecan, Hdc sn-38, Pen-866, 1472614-83-7, Sta 12-8666, Sdc-trap 0063

Molecular Formula

C₄₉H₄₉N₇O₉

Molecular Weight

880.0 g/mol

InChI Key

QTPZAEAYDWMVJO-GGCSAXROSA-N

FDA UNII

56DL1J49LR

Locnartecan is a miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.

1 2D Structure

Locnartecan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1H-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate

2.1.2 InChI

InChI=1S/C49H49N7O9/c1-5-31-33-20-30(8-9-38(33)50-43-35(31)24-55-40(43)22-37-36(45(55)59)25-64-46(60)49(37,63)6-2)65-48(62)54-16-12-27(13-17-54)11-15-53-18-14-28-19-29(7-10-39(28)53)56-44(51-52-47(56)61)34-21-32(26(3)4)41(57)23-42(34)58/h7-10,14,18-23,26-27,57-58,63H,5-6,11-13,15-17,24-25H2,1-4H3,(H,52,61)/t49-/m0/s1

2.1.3 InChI Key

QTPZAEAYDWMVJO-GGCSAXROSA-N

2.1.4 Canonical SMILES

CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C

2.1.5 Isomeric SMILES

CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C

2.2 Other Identifiers

2.2.1 UNII

56DL1J49LR

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Sta-12-8666

2. Sta-8666

2.3.2 Depositor-Supplied Synonyms

1. Locnartecan

2. Hdc Sn-38

3. Pen-866

4. 1472614-83-7

5. Sta 12-8666

6. Sdc-trap 0063

7. 56dl1j49lr

8. Hsp90-targeted Sn-38 Conjugate Pen-866

9. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1h-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate

10. Locnartecan [inn]

11. Pen866

12. Chembl4297475

13. Pen-866 [who-dd]

14. Schembl15522240

15. Schembl22223739

16. Sta-8666

17. Sb19799

18. (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-(propan-2-yl)phenyl)-5-oxo-1,5-dihydro-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)piperidine-1-carboxylate

19. 1-piperidinecarboxylic Acid, 4-(2-(5-(3-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)-, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl

20. 1-piperidinecarboxylic Acid, 4-(2-(5-(3-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl)-1h-indol-1-yl)ethyl)-, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester

2.4 Create Date

2019-01-15

3 Chemical and Physical Properties

Molecular Formula	C₄₉H₄₉N₇O₉
Molecular Weight	880.0 g/mol
XLogP3	5.4
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	10
Exact Mass	879.35917617 g/mol
Monoisotopic Mass	879.35917617 g/mol
Topological Polar Surface Area	199 Å²
Heavy Atom Count	65
Formal Charge	0
Complexity	1980
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1